FDA halts sale of painkiller Palladone

07/14/2005 | Wall Street Journal, The

The FDA said it had not received reports of major problems with the painkiller, which went on the market in February, but data from a Purdue Pharma study suggested that when Palladone was taken with alcohol, it could disable the drug's gradual-release mechanism and cause serious and perhaps fatal reactions. The suspension is a blow to Purdue Pharma, which had counted on Palladone to replace its blockbuster drug OxyContin, which is facing generic competition. A Purdue spokesperson said that, while the FDA action was "unanticipated," the company "complied with their request."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR
Director of Operations - GBS
Mayo Clinic
Rochester, MN